An observational study in Multisystem Inflammatory Syndrome in Children (MIS-C) and SARS-CoV-2 Infection, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Medical University of Warsaw · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system. Although acute cardiac abnormalities usually resolve, the long-term cardiovascular consequences of MIS-C remain uncertain. Previous follow-up of this cohort 2 years after MIS-C identified signs of subclinical cardiovascular abnormalities compared with healthy controls.
This cross-sectional study aims to evaluate cardiovascular health in individuals 5 years after MIS-C. Participants with a history of MIS-C will be compared with age- and sex-matched healthy controls using cardiovascular imaging, vascular assessments, cardiopulmonary exercise testing, and biomarkers of endothelial injury.
Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe hyperinflammatory condition associated with SARS-CoV-2 infection. Cardiovascular involvement is common during the acute phase of the disease and may include myocardial dysfunction, arrhythmias, hypotension, and coronary artery abnormalities. Although most patients experience rapid clinical recovery following immunomodulatory treatment, the long-term cardiovascular consequences of MIS-C remain incompletely understood.
The investigators previously evaluated cardiovascular health approximately 2 years after MIS-C and found evidence of subclinical cardiovascular abnormalities, including higher blood pressure values, increased concentrations of biomarkers associated with endothelial injury, and increased carotid intima-media thickness compared with healthy controls. These findings suggested that vascular changes may persist beyond the acute phase of the disease.
The aim of the present study is to assess cardiovascular health 5 years after MIS-C and to determine whether cardiovascular abnormalities remain detectable in long-term follow-up.
This is a cross-sectional study with a healthy control group. The MIS-C group will consist of individuals who were hospitalized with MIS-C at the Department of Pediatrics of the Medical University of Warsaw Children's Clinical Hospital between October 2020 and February 2021. Healthy controls will be recruited from primary care clinics and matched to the MIS-C group by age and sex.
All participants will undergo a comprehensive cardiovascular evaluation including:
The primary outcome is aortic (central) systolic blood pressure. Secondary outcomes include peripheral blood pressure, vascular stiffness parameters, carotid intima-media thickness, echocardiographic parameters, cardiopulmonary exercise test results, and concentrations of galectin-3, sICAM-1, and sVCAM-1. Outcomes will be compared between participants with a history of MIS-C and healthy controls to determine whether subclinical cardiovascular abnormalities persist 5 years after MIS-C.
The study is expected to provide important information regarding the long-term cardiovascular health of post-MIS-C patients and may help identify individuals who could benefit from ongoing cardiovascular surveillance.
29 studies on the registry are indexed under pediatric multisystem inflammatory disease, COVID-19 related; 8 are open to participants now.
This study's planned enrollment of 90 is below the median of 212 across 22 observational studies indexed under pediatric multisystem inflammatory disease, COVID-19 related.
Browse pediatric multisystem inflammatory disease, COVID-19 related studies →Medical University of Warsaw is the lead sponsor of 327 studies on the registry; 88 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study Population
MIS-C group: Individuals hospitalized at the Children's Clinical Hospital of the Medical University of Warsaw with a diagnosis of multisystem inflammatory syndrome in children (MIS-C) between October 2020 and February 2021.
Control group: Healthy age- and sex-matched individuals recruited from primary care clinics in Warsaw.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
MIS-C group:
Control group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children and young adults 5 years after MIS-C
Children and young adults without significant chronic disease, frequency-matched to the MIS-C group by age, sex, and BMI.
Aortic (central) systolic blood pressure
Central systolic blood pressure measured using pulse wave analysis.
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Peripheral blood pressure
Peripheral systolic and diastolic blood pressure measurements
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Arterial stiffness
Vascular stiffness assessed by pulse wave velocity and pulse wave analysis-derived parameters
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Carotid intima-media thickness
Carotid intima-media thickness measured by ultrasound
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Endothelial injury biomarker concentrations
Serum concentrations of galectin-3, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1)
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Echocardiographic parameters
Cardiac structure and function assessed by transthoracic echocardiography
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Cardiopulmonary exercise capacity
Exercise capacity and cardiopulmonary response assessed by cardiopulmonary exercise testing on a cycle ergometer.
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Comparison of cardiovascular outcomes between MIS-C participants and healthy controls
Comparison of cardiovascular, vascular, and endothelial function parameters between participants with a history of MIS-C and healthy controls.
Time frame: At the study visit, approximately 5 years after MIS-C diagnosis
Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
pediatric multisystem inflammatory disease, COVID-19 related →
Medical University of Warsaw →